Keyphrases
Adipocyte
10%
Adiponectin
10%
Adiponectin Receptor 1 (AdipoR1)
100%
Adiponectin Receptor 2
10%
AdipoR2
90%
Glucocorticoid Receptor
20%
Glucocorticoid Receptor Antagonist
10%
Glucose Metabolism
10%
Hepatocytes
100%
HepG2 Cancer Cells
10%
HepG2 Cells
10%
Lipid Metabolism
10%
Liver
30%
MRNA Level
10%
Peroxisome Proliferator-activated Receptor
40%
Peroxisome Proliferator-activated Receptor Agonists
100%
Protein Level
10%
Receptor Binding
10%
Rosiglitazone
100%
RU486
10%
Selective Glucocorticoid Receptor Modulators
10%
Therapeutic Effect
10%
Transcriptional Regulation
10%
Type 2 Diabetes Mellitus (T2DM)
10%
Type 2 Diabetes Prevention
20%
Medicine and Dentistry
Adipocyte
10%
Adiponectin
10%
Adiponectin Receptor
100%
Adiponectin Receptor 1
20%
Adiponectin Receptor 2
10%
Dexamethasone
10%
Glucocorticoid Receptor
30%
Glucocorticoid Receptor Antagonist
10%
Glucose Metabolism
10%
Hepatocyte
100%
Lipid Metabolism
10%
Maturity Onset Diabetes of the Young
30%
Messenger RNA
10%
Mifepristone
10%
Peroxisome Proliferator Activated Receptor
10%
Peroxisome Proliferator Activated Receptor Agonist
100%
Promoter Region
50%
Receptor Binding
10%
Rosiglitazone
100%
Therapy Effect
10%
Biochemistry, Genetics and Molecular Biology
Adipocyte
10%
Adiponectin
100%
Agonist
20%
Dexamethasone
10%
Glucocorticoid Receptor
40%
Glucose Metabolism
10%
Hepatocyte
100%
Lipid Metabolism
10%
Messenger RNA
10%
Peroxisome Proliferator-Activated Receptor
10%
PPAR Agonist
100%
Promoter Region
50%
Receptor Agonists
10%
Receptor Antagonist
10%
Receptor Binding
10%
Rosiglitazone
100%
Transcription
10%
Pharmacology, Toxicology and Pharmaceutical Science
Adiponectin
10%
Adiponectin Receptor
100%
Adiponectin Receptor 1
20%
Adiponectin Receptor 2
10%
Dexamethasone
10%
Glucocorticoid Receptor
30%
Glucocorticoid Receptor Antagonist
10%
Maturity Onset Diabetes of the Young
30%
Messenger RNA
10%
Mifepristone
10%
Peroxisome Proliferator Activated Receptor
10%
PPAR Agonist
100%
Receptor Agonist
10%
Rosiglitazone
100%
Therapeutic Effect
10%